SRRK Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Scholar Rock Holding's net margin of 21.68%. Scholar Rock Holding's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Scholar Rock Holding has a consensus price target of $49.67, signalling upside risk potential of 32.66%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.08%. Given that Scholar Rock Holding has higher upside potential than Eli Lilly and, analysts believe Scholar Rock Holding is more attractive than Eli Lilly and.

Scholar Rock Holding has a beta of 0.328, which suggesting that the stock is 67.196% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Scholar Rock Holding quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Scholar Rock Holding's net income of -$74.7M is lower than Eli Lilly and's net income of $2.8B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 82.18x versus 14.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of -53.36%. Scholar Rock Holding's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -49.57%.

Scholar Rock Holding has a consensus price target of $49.67, signalling upside risk potential of 32.66%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $423.14 which suggests that it could grow by 34.14%. Given that Madrigal Pharmaceuticals has higher upside potential than Scholar Rock Holding, analysts believe Madrigal Pharmaceuticals is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.328, which suggesting that the stock is 67.196% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -1.047, suggesting its less volatile than the S&P 500 by 204.702%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Scholar Rock Holding's net income of -$74.7M is lower than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 82.18x versus 21.66x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of 26.7%. Scholar Rock Holding's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Scholar Rock Holding has a consensus price target of $49.67, signalling upside risk potential of 32.66%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 28.32%. Given that Scholar Rock Holding has higher upside potential than Regeneron Pharmaceuticals, analysts believe Scholar Rock Holding is more attractive than Regeneron Pharmaceuticals.

Scholar Rock Holding has a beta of 0.328, which suggesting that the stock is 67.196% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Scholar Rock Holding's net income of -$74.7M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 82.18x versus 4.60x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Scholar Rock Holding's net margin of -60.08%. Scholar Rock Holding's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Scholar Rock Holding has a consensus price target of $49.67, signalling upside risk potential of 32.66%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 163.95%. Given that Sarepta Therapeutics has higher upside potential than Scholar Rock Holding, analysts believe Sarepta Therapeutics is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.328, which suggesting that the stock is 67.196% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Scholar Rock Holding's net income of -$74.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 82.18x versus 0.90x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.